Principal Investigator

Lucile Lauren
Adams-Campbell
Awardee Organization

Georgetown University
United States

Fiscal Year
2023
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

National Capital Area (NCA) Minority/Underserved NCORP

The National Capital Area (NCA) Minority/Underserved NCORP will be based at Georgetown Lombardi Comprehensive Cancer Center (LCCC), comprising Medstar Georgetown University Hospital (MGUH) and MedStar Washington Hospital Center (MWHC) as the primary affiliate, with a catchment area comprising 48.3% non-Latino Blacks (NLB) and 10.6% Hispanics/Latinos (H/L) that includes Washington, D.C. and adjacent counties in Maryland and Virginia. MWHC serves predominantly, i.e., > 85% minority and underserved populations; and treats more than 2,000 predominantly minority cancer patients and 48,000 outpatients, annually. The cancer burden and disparities are greatest among NLB population in the catchment area as evident by some of the highest mortality rates in the nation for breast, prostate, and colorectal cancers. Among the H/L population, cancer is the leading cause of death with H/L patients typically presenting at a later stage compared to Non-Latino White (NLW) patients. High rates of preventable cancer risk factors such as obesity, physical inactivity, and smoking, coupled with much lower screening rates for certain cancers, such as colorectal and cervical cancers in minorities contribute to the cancer disparities seen in the catchment area. The NCA NCORP proposes to address one of the most significant factors associated with these cancer disparities - limited access to optimal and cutting edge prevention, cancer control, and cancer care delivery by increasing awareness and providing access to cancer clinical trials among NLB and H/L in the catchment area. LCCC’s Office of Minority Health and Health Disparities Research (OMH), represents the community outreach arm that is led by Dr. Adams-Campbell, that has established viable academic-community partnerships that enable the NCA NCORP to conduct clinical research in areas of prevention, control, screening, health disparities, and cancer care delivery among the minority populations of interest. In light of an aging population and the increasing number of cancer survivors, this NCORP has the expertise and leadership as evident by demonstrable research in these areas that address cancer control and patient centered cancer care delivery. Furthermore, the ability to address cancer prevention and control among adolescents and young adults (AYA) is also a key strength of our team. The NCA NCORP will address the needs of our catchment area via cancer prevention, control, screening as well as treatment and imaging studies. The specific aims of the proposed National Capital Area NCORP are to: (1) Design and participate in clinical trials in cancer clinical research that improves the quality of care and the health outcomes of the US population in our catchment area; (2) Increase the participation of the greater DC area’s community oncologists and medical specialists and their patients in NCORP-led clinical research; and (3) Expand health disparities research focused on clinical research participation via community outreach, engagement, and education.

Publications

  • Ritchie EK, Klepin HD, Storrick E, Major B, Le-Rademacher J, Wadleigh M, Walker A, Larson RA, Roboz GJ. Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood advances. 2022 Jun 28;6(12):3812-3820. PMID: 35420672
  • Holstein SA, Suman VJ, Owzar K, Santo K, Benson DM Jr, Shea TC, Martin T, Silverman M, Isola L, Vij R, Cheson BD, Linker C, Anderson KC, Richardson PG, McCarthy PL. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Aug;26(8):1414-1424. Epub 2020 Apr 20. PMID: 32325171
  • Walter AW, Lee JW, Streck JM, Gareen IF, Herman BA, Kircher SM, Carlos RC, Kumar SK, Mayer IA, Saba NF, Fenske TS, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany-Afdhal CM, Shanafelt TD, Wagner LI, Land SR, Ostroff JS, Park ER. The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group trials. Cancer. 2024 Feb 1;130(3):439-452. Epub 2023 Oct 5. PMID: 37795845
  • Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. The New England journal of medicine. 2023 Mar 2;388(9):813-823. PMID: 36856617
  • Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Jan 10;41(2):186-197. Epub 2022 Sep 27. PMID: 36166727